摘要
目的探讨紫杉醇联合顺铂／卡铂在宫颈癌新辅助化疗中的作用。方法选择2003年2月～2006年7月经病理确诊的109例Ⅰb2期宫颈鳞癌患者作为研究对象。新辅助化疗联合手术治疗组（以下简称联合治疗组）58例，术前采用紫杉醇联合顺铂／卡铂化疗，2～3周后手术；另51例行单纯手术治疗（以下简称单纯手术组）。观察联合治疗组化疗1个疗程的有效率及2组术后宫颈深间质层浸润、脉管癌栓、淋巴结转移情况，同时观察新辅助化疗的毒副反应及评价新辅助化疗的安全性。结果联合治疗组中，完全缓解10例，部分缓解35例，稳定13例，进展0例，临床有效率为77．6％（45／58）；联合治疗组的肿瘤最大横径由化疗前的（4．46＋0．31）cm缩小为化疗后的（3．08＋0.22）cm，P〈0．05；联合治疗组与单纯手术组的术中出血量分别为（379.48＋169.45）ml及（398．82＋228．10）ml，P〉0．05；手术时间分别为（158．70＋20．27）min及（160．19＋25.82）min，P〉0.05；联合治疗组与单纯手术组的宫颈深层间质浸润发生率分别为55．2％（32／58）及56．9％（29／51），P〉0．05；脉管癌栓发生率分别为31．0％（18／58）及31．4％（16／51），P〉0．05；淋巴结转移率分别为22．4％（13／58）及25．5％（13／51），P〉0．05。在联合治疗组中，出现Ⅰ～Ⅲ度的骨髓抑制42例，占72．4％（42／58），经使用粒细胞集落刺激因子，骨髓抑制症状好转，血象恢复正常，无1例化疗相关死亡。结论紫杉醇联合顺铂／卡铂用于宫颈癌新辅助化疗，可缩小瘤体，提高宫颈癌的近期疗效。
Objective To investigate the effect of paclitaxel combined cisplatin in neoadjuvant chemotherapy （NAC） on cervical cancer. Methods Totally 109 case of cervical cancer in stage Ⅰb2 were diagnosed by pathlogy in our hospital from Febary 2001 to July 2006.58 patients were treated with one cycle of pclitaxel combined cisplatin, followed by radical surgery; 51 patients as control group were directly treated with radical surgery. The pathology in two group and the immediate respoand and toxicity in study group were observed to evaluate the effect and security of NAC. Results In study group, the rate of clinical response was 77.6 % （45/58）, 10 cases complery remission, 35 cases partly remission, 13 cases stabilizing. The volume of the tumors were diminished from （4.46＋0.31） cm to （3.08＋0.22） cm, P 〈 0.05; Surgery time, the volume of bleeding at surgery, pathology characters and lymph nide metastasis were nir observed significant difference P 〉 0.05. Conclusion Paclitaxel combined cisplatin in neoasjuvant chemotherapy （NAC） on cervical cancer can diminish the bolume of the tumirs. It shows promosing prospectin clinical application.
出处
《实用癌症杂志》
2006年第5期499-501,共3页
The Practical Journal of Cancer
关键词
紫杉醇
顺铂
卡铂
宫颈癌
新辅助化疗
Paclit axel
Cisplatin
Carboplatin
Cervical cancer
Neoadjuvant chemotherapy （NAC）
